Related Experiment Video
Updated: May 4, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
AR function in promoting metastatic prostate cancer
Michael A Augello1, Robert B Den, Karen E Knudsen
1Department of Cancer Biology, Thomas Jefferson University, 233 10th St., BLSB 1008, Philadelphia, PA, 19107, USA, Michael.augello@jefferson.edu.
Abstract:
Prostate cancer (PCa) remains a leading cause of cancer-related death in the USA. While localized lesions are effectively treated through radical prostatectomy and/or radiation therapy, treatment for metastatic disease leverages the addiction of these tumors on the androgen receptor (AR) signaling axis for growth and disease progression. Though initially effective, tumors resistant to AR-directed therapeutics ultimately arise (a stage of the disease known as castration-resistant prostate cancer) and are responsible for PCa-specific mortality. Importantly, an abundance of clinical and preclinical evidence strongly implicates AR signaling cascades in the development of metastatic disease in both early and late stages, and thus a concerted effort has been made to delineate the AR-specific programs that facilitate progression to metastatic PCa. A multitude of downstream AR targets as well as critical AR cofactors have been identified which impinge upon both the AR pathway as well as associated metastatic phenotypes. This review will highlight the functional significance of these pathways to disseminated disease and define the molecular underpinnings behind these unique, AR-driven, metastatic signatures.
Insights
Prostate cancer progression to metastatic stages is driven by androgen receptor (AR) signaling. Understanding AR-specific pathways is crucial for developing effective treatments for advanced prostate cancer (PCa).
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer (PCa) is a major cause of cancer mortality in the USA.
- Localized PCa is treatable, but metastatic disease requires targeting the androgen receptor (AR) signaling axis.
- Tumors eventually develop resistance, leading to castration-resistant prostate cancer (CRPC) and PCa-specific death.
Purpose of the Study:
- To review the functional significance of AR signaling pathways in prostate cancer metastasis.
- To define the molecular underpinnings of AR-driven metastatic signatures.
- To highlight AR's role in both early and late-stage metastatic disease.
Main Methods:
- Review of clinical and preclinical evidence implicating AR signaling in metastasis.
- Identification of downstream AR targets and cofactors involved in metastatic phenotypes.
- Analysis of AR-specific programs facilitating metastatic PCa progression.
Main Results:
- AR signaling cascades are strongly implicated in the development of metastatic PCa.
- Numerous downstream AR targets and cofactors influence AR pathway and metastatic phenotypes.
- AR-driven metastatic signatures are linked to disease progression.
Conclusions:
- AR signaling is a critical driver of prostate cancer metastasis.
- Understanding AR-specific pathways is key to targeting metastatic PCa.
- Further research into AR-driven metastatic signatures may reveal novel therapeutic strategies.
